 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...345678910111213...507508» |
- | doxorubicin hydrochloride / Generic mfg.
Journal: Bimetallic DNAsome Decorated with G4-DNA as a Nanozyme for Targeted and Enhanced Chemo/Chemodynamic Cancer Therapy. (Pubmed Central) - Apr 26, 2024
DNA-based surface addressability of the DNAsome is then used for the integration of second Fenton reaction center, which is a peroxidase-mimicking DNAzyme noncovalently loaded with Hemin and Doxorubicin, via DNA hybridization to give a CDT agent having dual Fenton reaction centres...Targeted internalization of the CDT nanoagent and selective generation of
- | doxorubicin hydrochloride / Generic mfg.
Journal: Role of the ?2-adrenergic receptor in podocyte injury and recovery. (Pubmed Central) - Apr 26, 2024
DNA-based surface addressability of the DNAsome is then used for the integration of second Fenton reaction center, which is a peroxidase-mimicking DNAzyme noncovalently loaded with Hemin and Doxorubicin, via DNA hybridization to give a CDT agent having dual Fenton reaction centres...Targeted internalization of the CDT nanoagent and selective generation of These results indicate that the podocyte ?2-AR is a critical component of the recovery mechanism and may serve as a novel therapeutic target for treating podocytopathies.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Exosomes miRNA-499a-5p targeted CD38 to alleviate anthraquinone induced cardiotoxicity: experimental research. (Pubmed Central) - Apr 26, 2024
These results indicate that the podocyte ?2-AR is a critical component of the recovery mechanism and may serve as a novel therapeutic target for treating podocytopathies. In this study, C-B-exo-miRNA-499a-5p significantly improved DOX-induced cardiotoxicity via CD38/MAPK/NF-?B signal pathway, providing a new idea and method for the treatment of DOX induced cardiotoxicity.
- | Retrospective data, Journal, Machine learning: A Radiogenomic multimodal and whole-transcriptome sequencing for preoperative prediction of axillary lymph node metastasis and drug therapeutic response in breast cancer: a retrospective, machine learning And international multi-cohort study. (Pubmed Central) - Apr 26, 2024
Overall, the radiogenomic multimodal model employs multimodal data, including radiological images, genetic, and clinicopathological typing. The radiogenomic multimodal nomogram can precisely predict ALNM and drug therapeutic response in BC patients.
- | doxorubicin hydrochloride / Generic mfg.
Journal: A Novel Interaction of Slug (SNAI2) and Nuclear Actin. (Pubmed Central) - Apr 26, 2024
Since both proteins have been reported to be involved in DNA double-strand break (DSB) repair, we focused on their interaction during this process after treatment with doxorubicin or UV irradiation. Confocal microscopy elicits that the overexpression of actin fused to an NLS stabilizes complexes of slug and ?H2AX, an early marker of DNA damage repair.
- | ibuprofen / Generic mfg.
Journal: Design, synthesis, and cytotoxicity of ibuprofen-appended benzoxazole analogues against human breast adenocarcinoma. (Pubmed Central) - Apr 26, 2024
unveiled their best docking scores and binding interactions in agreement to experimental results. Pharmacokinetics prediction envisaged their drug-like properties suitable for therapeutic applications.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Nitrogen-containing andrographolide derivatives with multidrug resistance reversal effects in cancer cells. (Pubmed Central) - Apr 26, 2024
Moreover, all selected compounds displayed synergistic interaction with doxorubicin, with compound 3 being the most active. In the ATPase assay, selected compounds exhibited characteristics of P-gp inhibitors.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Zirconium-Containing Nanoscale Coordination Polymers for Positron Emission Tomography and Fluorescence-Guided Cargo Delivery to Triple-Negative Breast Tumors. (Pubmed Central) - Apr 25, 2024
Doxorubicin was loaded on Zr-P1 NCP with encapsulation efficiency up to 22% for the treatment of triple negative breast cancer...89Zr-P1@PEG-RGD nanomaterials have positron emission tomography (PET) capability due to the incorporation of zirconium-89, which can be used for in vivo tumor imaging with high sensitivity. The chemotherapeutic drug DOX was loaded on Zr-P1 NCP for the treatment of triple-negative breast cancer, and dual modality imaging can provide visual guidance for drug delivery.
- | TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Journal: A Nanomedicine Composed of Polymer-ss-DOX and Polymer-Ce6 Prodrugs with Monoclonal Antibody Targeting Effect for Anti-tumor Chemo-Photodynamic Synergetic Therapy. (Pubmed Central) - Apr 25, 2024
By coupling antibodies to the hydrophilic segments of polymer micelles, drugs can be specifically delivered. Compared with monotherapy, the combination of chemotherapy and photodynamic therapy can significantly enhance the therapeutic effect of liver cancer.
- | Recentin (cediranib) / AstraZeneca
Preclinical, Journal: Microsphere-Enabled Modular Formation of Miniaturized In Vitro Breast Cancer Models. (Pubmed Central) - Apr 25, 2024
Evaluation of anticancer drugs such as doxorubicin and Cediranib on the tumor models do demonstrate corresponding physiological responses. Clearly, with the ability to modulate microsphere morphology, cell composition and spatial distribution, microsphere-enabled 3D tumor tissue formation offers a high flexibility to satisfy the needs for pathophysiological study, anticancer drug screening or design of personalized treatment.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma. (Pubmed Central) - Apr 25, 2024
Clearly, with the ability to modulate microsphere morphology, cell composition and spatial distribution, microsphere-enabled 3D tumor tissue formation offers a high flexibility to satisfy the needs for pathophysiological study, anticancer drug screening or design of personalized treatment. The canine 1E4-cIgGB anti-CD20 monoclonal antibody is apparently safe when administered with doxorubicin and effectively depletes B-cells in dogs with DLBCL.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Crocin, the compound of the dried stigma of Crocus sativus L (saffron), restores doxorubicin-induced disturbances in kidney functioning, oxidative stress, inflammation, renal tissue morphology and TGF-? signalling pathways. (Pubmed Central) - Apr 25, 2024
in Dox-induced nephrotoxicity. Conclusionally, Cr exhibits adequate nephroprotective effects against Dox-induced nephrotoxicity on rat kidney architecture and tissue function by stabilising cellular redox homeostasis, reducing renal fibrosis and suppressing inflammation.
- | doxorubicin hydrochloride / Generic mfg., docetaxel / Generic mfg.
Journal: Alginate/carboxymethyl chitosan core-shell microspheres co-loaded with docetaxel/doxorubicin reverse chemotherapy resistance in anaplastic thyroid carcinoma. (Pubmed Central) - Apr 25, 2024
A-DOX@C-DTX microspheres exhibited superior anti-tumor effects compared to free drug treatment both in vitro and in vivo, particularly against drug-resistant ATC cells. This improved therapeutic efficacy may be attributed to the enhanced drug uptake and reduced drug efflux in drug-resistant ATC cells facilitated by ALG/CMC microspheres.
- | dactolisib (RTB101) / Adicet Bio
Preclinical, Journal: Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt Lymphoma RAJI Cell Line (Pubmed Central) - Apr 25, 2024
The constitutive activation of PI3K/AKT/mTOR pathway of RAJI/DOX cell line was more serious than RAJI cell line. NVP-BEZ235 reversed doxorubicin resistance of RAJI/DOX cell line by inhibiting the PI3K/AKT/mTOR signal pathway.
- | doxorubicin hydrochloride / Generic mfg.
Journal, IO biomarker: Reversal Effect of Arctigenin on the Drug Resistance in Leukemia K562/A02 Cells and Its Mechanism (Pubmed Central) - Apr 25, 2024
NVP-BEZ235 reversed doxorubicin resistance of RAJI/DOX cell line by inhibiting the PI3K/AKT/mTOR signal pathway. ARG may reverse the resistance of human leukemia cell line K562/A02 to ADM by inhibiting TLR4/NF-?B signaling pathway.
- | Rydapt (midostaurin) / Novartis, Vanflyta (quizartinib) / Daiichi Sankyo
Preclinical, Journal: Correlation of miR-155 Expression with Drug Sensitivity of FLT3-ITD+ Acute Myeloid Leukemia Cell Line and Its Mechanism (Pubmed Central) - Apr 25, 2024
ARG may reverse the resistance of human leukemia cell line K562/A02 to ADM by inhibiting TLR4/NF-?B signaling pathway. Drug sensitivity of MV411 cells to doxorubicin, quizartinib and midostaurin can be enhanced significantly after miR-155 knockout, which is related to the inhibition of multiple signaling pathways including mTOR and Wnt signaling pathways.
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Trial suspension: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma (clinicaltrials.gov) - Apr 25, 2024
P1, N=50, Suspended, Sponsor: University of Washington
Drug sensitivity of MV411 cells to doxorubicin, quizartinib and midostaurin can be enhanced significantly after miR-155 knockout, which is related to the inhibition of multiple signaling pathways including mTOR and Wnt signaling pathways. Recruiting --> Suspended
- Survival outcomes in patients with primary plasma cell leukemia treated with novel therapies at University of California San Diego Health: A single institution experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6915;
The small sample size and heterogeneity of the treatments prohibited correlative statistical analysis. Prospective studies are needed to determine the best treatment option for this high-risk population which is excluded from most myeloma trials.
- Herceptin (trastuzumab) / Roche
Effect of fructose on anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: New roles of sweeteners in cardio-oncology. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6846;
Human cardiomyocytes were pre-exposed with doxorubicin combined to trastuzumab (at 300 and 1000 nM) for 48 and 72h alone or combined to fructose at 0. Data of the present study indicate that fructose induces a pro-inflammatory phenotype in human cardiac cells exposed to anticancer cardiotoxic drugs, providing even more data on the harmful role of fructose as a key player of cardiotoxic phenomena.
- ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Molecular characteristics of dedifferentiated liposarcoma with broad rhabdomyosarcomatous differentiation. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6832;
This NGS analysis disclosed the possible progression mechanisms and therapeutic targets in DDLPS with broad rhabdomyosarcomatous differentiation and provided insights contributing to the refinement of management in this tumor. >AI, adriamycin and ifosfamide; RFS, recurrence-free survival.
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Is the gemcitabin cisplatin doublet the optimal induction chemotherapy for non-Asian patients with NPC? Insights from a northeastern Moroccan cohort. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6738;
In patients with locally advanced nasopharyngeal carcinoma, GC-based induction chemotherapy demonstrated superior ORR over the DP regimen with acceptable toxicities. Further studies are needed to validate these results.
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Efficacy and safety of anthracycline combined with alkylating agent for treatment of advanced leiomyosarcoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6720;
EPI-TMZ is potentially effective for treatment of advanced LMS, and the adverse effects appear tolerable. EPI-TMZ may provide better outcomes than reported in previous studies of other treatments for advanced LMS, worth further prospective research.
- Opdivo (nivolumab) / BMS
Update on GALLANT: A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in previously treated sarcoma (NCT04535713). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6717;
P2
Taken together, the data suggests that nivolumab plus metronomic doses of gemcitabine, doxorubicin and docetaxel (1) may have synergistic activity, and (2) by indirect comparison, may be as effective as standard first line therapy for advanced sarcoma with manageable toxicity. Clinical trial information: NCT04535713.
- Treatment of relapsed small cell lung cancer in the real-world: A comparison of platinum-etoposide rechallenge and cyclophosphamide-doxorubicin-vincristine (CAV) chemotherapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6674;
Patients who receive second-line systemic therapy for relapsed SCLC represent a small subset of the overall SCLC patient population. In this real-world study, platinum-etoposide re-challenge appeared to offer benefit over CAV, even in patients with PFI < 180 days.
- Zepzelca (lurbinectedin) / PharmaMar, Jazz
Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6672;
2L lurbinectedin efficacy appeared limited, similar to other platinum-free regimens, yet I was mostly used in platinum-resistant pts. Further data is needed to explore the potential of first-line IO in enhancing sensitivity to platinum rechallenge.
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant treatment with camrelizumab in combination with doxorubicin and ifosfamide: A phase II clinical study of high-risk soft tissue sarcoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6545;
P2
Survival follow-up is still ongoing to analyze the effect of perioperative immunotherapy combined with chemotherapy on long-term outcomes of pts with soft tissue sarcoma. Clinical trial information: NCT04606108.
- ifosfamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Assessing response and adherence to neoadjuvant treatment in soft tissue sarcomas of the extremities. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6505;
The main cause of treatment delay at our center was due to overcapacity; however, this did not influence the pathological response relative to dose intensity. Additional follow-up assessments are required to determine the influence on relapse-free and overall survival based on the response after preoperative CRT.
- ifosfamide / Generic mfg., mesna / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical features, molecular findings, and clinical outcomes of follicular dendritic cell sarcoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6503;
Advanced diseases generally do not respond to multimodality therapy including immunotherapy but can have disease stabilization with variable survival. CDKN2A/B mutations were common and potentially associated with a worse outcome.
- Votrient (pazopanib) / Novartis, BeiGene
Epithelioid hemangioendothelioma: Real-world data about a rare entity in a Portuguese tertiary cancer center. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6470;
In our cohort, the majority of patients presented with distant metastasis, but the course of the disease was very heterogeneous, regardless of the primary or metastatic site or the treatment modality. Our data emphasizes that this disease should be managed on a case-by-case basis, with a multidisciplinary approach and tailored treatment and surveillance.
- ADG106 / Adagene
A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6398;
P1/2
The RP2D of ADG106 in combination with P is 200mg and is safe and tolerable; manageable G3 neutropenia was the most common AE. There are no new safety signals thus far in Phase II.
- doxorubicin hydrochloride / Generic mfg.
Analysis of regulation of cell death pathway genes in CSC-enriched TNBC after treatment with doxorubicin: A potencial biomarker. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6157;
Previous studies of our group have shown that achieving a satisfactory result of DOX action on CSCs-enriched spheroids requires using a dose 100 times higher than that used in monolayer cells. This may be related to the non-expression of the TNFRSF10B, TNFRSF10C, RIPIK1, CASP8, and MLKL genes in CSCs-enriched spheroid DOX-treated.
- Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6096;
This indirect comparison suggests that EV+P has a favorable survival benefit compared with other approved and investigational 1L regimens in patients with previously untreated la/mUC. >ddMVAC: dose dense methotrexate, vinblastine, doxorubicin, cisplatin; PBC: platinum-based chemotherapy.
- paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6020;
The facilitation of cisplatin-based regimens after GTA in a subset of pts might be explained by restoring patency in partially obstructed collecting systems. This 'GTA bridging' strategy may be beneficial for pts for whom nephrostomy or ureteral stenting proves impractical or insufficient to address renal insufficiency.
- maplirpacept (TTI-622) / Pfizer
A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5994;
P1/2
The encouragingly tolerable dose of 48mg/kg thus represents the RP2D which could support further development for this population. Clinical trial information: NCT05261490.
- progerinin (SLC-D011) / PRG S&Tech
CRS-HIPEC following neo-adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy in primarily advanced inoperable epithelial ovarian cancer: An ISPSM collaborative study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5985;
CRS-HIPEC following neo-adjuvant PIPAC + IV chemotherapy is safe, feasible and tolerable. PIPAC repeated every 4-5 weeks along with systemic chemotherapy provides a ideal scenario to monitor & assess response to loco regional and systemic chemotherapy.
- Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5623;
In patients who developed irAEs, we found a significant elevation in ITAC, a chemokine induced by IFN-gamma that attracts activated T cells. Other inflammatory cytokines such as IL-6, IL-13, IL-17, and MIP-1b trended towards significance, likely due to the small sample size.
- Immune checkpoint inhibitor-related reproductive adverse effects: A pharmacovigilance analysis based on the FAERS database. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5613;
Additional therapies could change the risk of irRAEs. Despite the current lack of high-quality clinical data on this topic, it is reasonable to inform patients about the plausible risk of irRAEs.
- Yolk sac tumor of the liver: Presentation, diagnosis, and treatment review. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5270;
YSTL is a unique tumor presenting in patients of all ages, tending to present vaguely often with abdominal pain or distension. Diagnostic workup often includes abdominal imaging (MRI and CT Abdomen) and pathology with a focus on SDBs on histologic examination and stains like AFP, A1AT, SALL4, etc. Treatment often focuses on surgery and chemotherapy, notably BEP.
- doxorubicin hydrochloride / Generic mfg.
Exosome-delivered microRNAs confer adriamycin-resistance through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5207;
Doxorubicin-resistant cells can transmit drug-resistance to sensitive cells via delivering miR-222 by modulating the immune- and metabolism-related gene PTEN without interference from other relevant drug-resistance factors in exosomes. Therefore, miR-222-containing exosomes and their target gene PTEN may be a promising biomarker for predicting chemotherapy efficacy and tumor immunity regulation in BCa patients receiving anthracycline chemotherapy.
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Real life comparison between doxorubicin and cyclophosphamide (AC) dose-dense (dd) and conventional dose AC in patients with triple negative breast cancer (TNBC) under neoadjuvant treatment. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5164;
We performed a retrospective observational cohort study of patients with early TNBC, stage I-III who received neoadjuvant treatment with chemotherapy based on doxorubicin, cyclophosphamide, paclitaxel and carboplatin associated with pembrolizumab. AC dd was more prevalent in our series, despite the additional use of granulocyte growth factor, there were more complications in this group and it did not demonstrate better results than those who received conventional dose AC.
- An open-label randomized trial comparing addition of olanzapine 5 mg versus olanzapine 10 mg as anti-emetic to standard anti-emetic regime for doxorubicin or epirubicin and cyclophosphamide in breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5155;
However, Olanzapine 10 mg was associated with higher proportions of somnolence and fatigue. Therefore, it is recommended that Olanzapine 5 mg may replace current antiemetic regimes that contain Olanzapine 10 mg.
- Results of neoadjuvant therapy for patients with triple negative breast cancer in a public hospital in Brazil (Federal District). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5139;
Triple negative patients were young and tended to have at least one comorbidity in addition to a highest rate of locally advanced tumor. The more aggressive protocol (AC-TC) was used less often, but has a higher rate of cRP and should be used more frequently in this scenario despite the greater complexity of these patients.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5120;
P=N/A
The more aggressive protocol (AC-TC) was used less often, but has a higher rate of cRP and should be used more frequently in this scenario despite the greater complexity of these patients. Background: Inetetamab, a novel monoclonal antibody targeting HER2, alters the Fc region amino acids, which induces ADCC stronger than trastuzumab...Eligible patients will be administered six cycles of neoadjuvant treatment, including carboplatin (AUC=6mg/mL
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A retrospective, single-center study comparing two neoadjuvant protocols for patients with HER2-positive breast cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5111;
In this study, pCR rates were numerically better in the ACTHP regimen vs. DCHP, though not statistically significant. Dose reductions were more common in the DCHP but had less cardiotoxicity.
- Keytruda (pembrolizumab) / Merck (MSD)
Real life data of KEYNOTE 522: The Cleveland Clinic experience. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5098;
Notably, the dose reduction or discontinuation of agents did result in a deterioration of PCR rate compared to patients completing full therapy. Remarkably, PCR was improved for the pembrolizumab discontinuation group, perhaps suggesting a correlation between autoimmune toxicities and improved response.
- Keytruda (pembrolizumab) / Merck (MSD)
Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5086;
Despite more dose interruptions with pembro, the 1-year EFS and OS were not significantly affected. While the more recent 5-year results from the KEYNOTE-522 trial have validated enhanced EFS, with OS data yet to mature, our findings didn't reveal clear short-term benefits.
- Rituxan (rituximab) / Roche
Clinical features and outcomes of patients with follicular lymphoma grade 3A: A real-world study in single center. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5043;
55% of all FLs, with a median age of 57 years old and mostly in the advanced stage. FL3A has a long survival period, with a 5-year PFS of 73%.
- Lunsumio (mosunetuzumab-axgb) / Roche, Biogen
Efficacy and safety of mosunetuzumab-based regimens as first-line therapy in non-Hodgkin lymphomas: A systematic review of clinical trials. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5029;
Subcutaneous mosunetuzumab was active in follicular lymphoma with manageable toxicity in follicular lymphoma. However, long-term results are needed to determine the durability of responses and long-term safety and survival rates with these regimens.
- Rituxan (rituximab) / Roche
Long term results of a new treatment strategy for follicular low grade lymphoma (FLGL). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5024;
Our data highlight the need to 1- identify CDIH for potential use of doxorubicin treatment. 2- CDIH as prognostic factor seems more effective than FLIPI-2.
- dexamethasone sodium phosphate (AVM0703) / AVM Biotechnology, Rituxan (rituximab) / Roche
Effect of AVM0703 treatment on the limitations of R-CHOP and survival in a model applicable to ABC subtype DLBCL. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4994;
AVM+RCHOP demonstrated anti-tumor activity in A20 lymphoma mice, with reduced toxicity, compared to RCHOP. Larger preclinical studies are underway to confirm the activity of AVM0703+RCHOP against RCHOP resistant ABC DLBCL, and the potential to reduce total RCHOP exposure to only 3 cycles while maintaining or improving efficacy.